PA22-176, sbir, phase i, development of a sars-COV-2 emerging variant infectivity and immune evasion panel to quantify the efficacy of vaccine booster induced neutralizing antibodies
Ended Cooperative Agreement Awarded Last action
- Award ID
- R43IP001230
- Recipient
-
Virongy Biosciences Inc. UEI XGY3Q7EZ9JA7
- Awarding agency
-
Office of Financial Resources
Centers for Disease Control and Prevention, Department of Health and Human Services
- Obligated
- $546,362
Award facts
- Assistance listing
- 93.283 Centers for Disease Control and Prevention Investigations and Technical Assistance
- Completion date
- Originally
- Funding agency
- Office of the Director Centers for Disease Control and Prevention, Department of Health and Human Services
- Place of performance
- Virginia, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $273,181 | |
| Original award | $273,181 |
Quick answers
Who received award R43IP001230?
R43IP001230 was awarded to Virongy Biosciences Inc. by Office of Financial Resources (Centers for Disease Control and Prevention) on September 30, 2023.
How much is award R43IP001230 worth?
$546,362 has been obligated on R43IP001230.
Which agency awarded R43IP001230?
Office of Financial Resources (Centers for Disease Control and Prevention) awarded R43IP001230, with funding from Office of the Director (Centers for Disease Control and Prevention).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award